Fractyl Health (NASDAQ:GUTS) Stock Price Up 4.5% – What’s Next?

Fractyl Health, Inc. (NASDAQ:GUTS)’s stock price shot up 4.5% during mid-day trading on Wednesday . The stock traded as high as $2.12 and last traded at $2.09. 3,551,112 shares were traded during mid-day trading, an increase of 20% from the average session volume of 2,957,027 shares. The stock had previously closed at $2.00.

Analyst Upgrades and Downgrades

A number of research firms recently commented on GUTS. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a report on Tuesday, December 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Fractyl Health in a research report on Monday, December 29th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a research report on Friday, December 19th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $7.40.

Fractyl Health Stock Performance

The firm has a market capitalization of $286.41 million, a P/E ratio of -0.91 and a beta of 1.62. The firm’s 50-day moving average is $1.77 and its 200 day moving average is $1.49.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). As a group, research analysts expect that Fractyl Health, Inc. will post -1.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Fractyl Health

Institutional investors have recently made changes to their positions in the company. Woodline Partners LP grew its position in shares of Fractyl Health by 47.2% during the 1st quarter. Woodline Partners LP now owns 516,921 shares of the company’s stock worth $615,000 after purchasing an additional 165,786 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of Fractyl Health in the second quarter valued at approximately $181,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of Fractyl Health in the second quarter valued at approximately $26,000. Qube Research & Technologies Ltd acquired a new stake in Fractyl Health during the second quarter worth approximately $129,000. Finally, General Catalyst Group Management LLC bought a new position in Fractyl Health during the 2nd quarter worth $7,912,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.